2015 was a watershed year for pharma’s investment in relationships with patient groups and patientcentric activities.
Many of the major pharma companies announced new strategies to expand their patient centricity (some are outlined in this latest report).
The step-up in interest among patient groups can be seen in the fact that ...
- The pharma industry's corporate reputation stands, in 2015, at its best ever since these PatientView surveys began in 2011. 44.7% of the 1,075 respondent patient groups stated that pharma had an “Excellent” or “Good” corporate reputation in 2015, compared with 34% in 2012 (when the industry’s corporate reputation reached its lowest ebb). 28% of 2015’s respondent patient groups believed the industry’s corporate reputation to have improved during the year.
- The main reason given by patient groups for the positive feedback in 2015 was pharma’s ability to produce highquality products of value to patients. As many as 72% of the 1,075 patient groups responding to the 2015 ‘Corporate Reputation of Pharma’ survey stated that the pharma industry as a whole was “Excellent” or “Good” during the year at producing high-quality products. This finding is the highest percentage that PatientView has ever recorded for this particular question throughout the five years in which the ‘Corporate Reputation’ survey has been conducted.
However, patient groups retain reservations about pharma—in particular, about the industry's pricing practices ...
- Only 15% of the patient groups responding to the 2015 survey stated that pharma was “Excellent” or “Good” at having fair pricing policies (and at not making excessive profits). As many as 45% of 2015’s respondent patient groups said that pharma was poor at this activity.
The patient groups most aggrieved about pharma’s pricing are those specialising in hepatitis, HIV/AIDS, and rare diseases. In country terms, the most unhappy are patient groups in Australasia, France, Germany, the Netherlands, the UK, and the USA.